XI'AN, China, March 23, 2011 /PRNewswire-Asia-FirstCall/ -- Huifeng Bio-Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB) ("Huifeng" or "the Company"), specializing in developing and producing botanical extracts and other raw materials for pharmaceuticals and food additives, today announced the appointment of Ms. Amy Xue to Senior Vice President of Finance.
"We are truly delighted that Ms. Xue will be a part of the Company," said Jing'an Wang, Founder, Chairman, and Chief Executive Officer of Huifeng. "Her appointment is an important step in strengthening the Company's internal controls over financial reporting. Ms. Xue brings a tremendous amount of knowledge and strategic counsel to our senior management team and we are fully confident that she will play an integral role in the achievement of Huifeng's growth and financial goals."
Ms. Xue has extensive experience in U.S. GAAP financial reporting and public accounting, and she has performed audit and accounting services for companies in a variety of industries. In 2010, she founded Farolfi & Company, LLC, a New York based accounting and business advisory firm. Prior to that, Ms. Xue was a senior manager of Acquavella, Chiarelli, Shuster, Berkower & Co., LLP, a public accounting firm in New York that focuses on SEC audits with Chinese companies.
Ms. Xue holds a Master's in accounting from Binghamton University and a B.S. in law from Peking University in Beijing, China. She is a U.S. Certified Public Accountant in New York and a member of the American Institute of Certified Public Accountants (AICPA).
About Huifeng Bio-Pharmaceutical Technology, Inc.Huifeng Bio-Pharmaceutical Technology, Inc., located in Xi'an, People's Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of rutin and related plant-derived chemicals in a class called flavonoids, with medicinal and other beneficial properties. Founded in 2002, Huifeng uses proprietary patented processes to extract rutin more efficiently than traditional extraction techniques. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organizations. More information can be found on the Company's web site at: http://www.hfgb.cn/
Safe Harbor StatementThis release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors.Investor Contact:Mr. Kevin FickleNUWA Group, LLCTel: +1-925-330-8315Email: Kevin@nuwagroup.comCompany Contact:Ms. Bing HeHuifeng Bio-Pharmaceutical Technology, Inc.Tel: +86-139-9195-4170Email: firstname.lastname@example.org
|SOURCE Huifeng Bio-Pharmaceutical Technology, Inc.|
Copyright©2010 PR Newswire.
All rights reserved